COST

1,012.46

+1.7%↑

78.4

-0.99%↓

146.11

-1.24%↓

171.16

+0.32%↑

PEP

156.25

+0.22%↑

COST

1,012.46

+1.7%↑

78.4

-0.99%↓

146.11

-1.24%↓

171.16

+0.32%↑

PEP

156.25

+0.22%↑

COST

1,012.46

+1.7%↑

78.4

-0.99%↓

146.11

-1.24%↓

171.16

+0.32%↑

PEP

156.25

+0.22%↑

COST

1,012.46

+1.7%↑

78.4

-0.99%↓

146.11

-1.24%↓

171.16

+0.32%↑

PEP

156.25

+0.22%↑

COST

1,012.46

+1.7%↑

78.4

-0.99%↓

146.11

-1.24%↓

171.16

+0.32%↑

PEP

156.25

+0.22%↑

Home・Akciju saraksts・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Slēgts

SektorsPatēriņa aizsardzības

4.76 -4.23

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.72

Max

4.95

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.9M -10M
Pārdošana	-5.3M 31M
Peļņas marža	-32.116
Darbinieki	400

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+10.89% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-66M 175M
Iepriekšējā atvēršanas cena	8.99
Iepriekšējā slēgšanas cena	4.76

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. maijs 23:58 UTC

Peļņas

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026. g. 7. maijs 22:57 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026. g. 7. maijs 23:52 UTC

Peļņas

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026. g. 7. maijs 23:45 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 7. maijs 23:39 UTC

Tirgus saruna

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026. g. 7. maijs 23:28 UTC

Tirgus saruna

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026. g. 7. maijs 23:11 UTC

Peļņas

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026. g. 7. maijs 23:06 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026. g. 7. maijs 23:05 UTC

Peļņas

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026. g. 7. maijs 23:04 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026. g. 7. maijs 23:02 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026. g. 7. maijs 23:00 UTC

Tirgus saruna

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026. g. 7. maijs 22:42 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026. g. 7. maijs 22:33 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026. g. 7. maijs 22:32 UTC

Peļņas

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie: 68% of FY Income From International >MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026. g. 7. maijs 22:29 UTC

Peļņas

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026. g. 7. maijs 22:26 UTC

Peļņas

Macquarie to End Share Buyback Extended in November>MQG.AU

2026. g. 7. maijs 22:25 UTC

Peļņas

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Cenas mērķis

By TipRanks

10.89% augšup

Prognoze 12 mēnešiem

Vidējais 5.5 USD 10.89%

Augstākais 6 USD

Zemākais 5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.